Results 81 to 90 of about 314,028 (218)

Advances in Gastric Cancer Research: Insights Into Carcinogenesis, the Tumor Microenvironment, Metastasis, and Factors Influencing Prognosis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Department of Gastroenterological Surgery at Kumamoto University has maintained a commitment to integrating cutting‐edge clinical practice with fundamental research, particularly concerning malignant diseases of the digestive tract.
Hideo Baba   +4 more
wiley   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya   +2 more
wiley   +1 more source

Risks and Benefits of Feeding Enterostomy Creation During Minimally Invasive Esophagectomy: A Propensity‐Weighted Analysis Using the Japanese National Clinical Database

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Feeding enterostomy during MIE was evaluated in 19 054 patients from the Japanese NCD using propensity weighting. Enterostomy was associated with higher reoperation and respiratory complications, but lower delayed gastric emptying and deep vein thrombosis, with no significant difference in overall bowel obstruction.
Eisuke Booka   +7 more
wiley   +1 more source

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki   +9 more
wiley   +1 more source

Toward Precision Cancer Immunotherapy

open access: yes
Advanced Science, EarlyView.
Shuang Tang   +2 more
wiley   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu   +9 more
wiley   +1 more source

Systematic Review and Meta‐Analysis on the Efficacy and Safety of Salvage Esophagectomy for T4 Esophageal Squamous Cell Carcinoma

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This meta‐analysis of 208 cases shows that salvage esophagectomy for cT4 esophageal squamous cell carcinoma achieves a 72% R0 resection rate, offering a curative pathway for selected patients. However, it remains a high‐risk procedure with an 18% anastomotic leak rate and 30% major complications (Clavien–Dindo ≥ III).
Makoto Sakai   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy